Prognostic Indicators of Survival in Advanced Endometrial Cancer

Behbakht, Kian; Yordan, Edgardo; Casey, Caroline; DeGeest, Koen; Massad, L. Stewart; Kirschner, Caroline; Wilbanks, George D.

doi:10.1006/gyno.1994.1307

Cited by 35 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study confirms the previously established prognostic impact of age and FIGO stage (2,3,22,23). Furthermore, tumor biomarkers related to cell-cycle regulation (p53) and apoptosis (bcl-2) were found to be associated with prognosis, whereas angiogenesis was not.…”

Section: Discussionsupporting

confidence: 89%

Angiogenesis, p53, and bcl-2 Expression as Prognostic Indicators in Endometrial Cancer

Erdem

Dursun

et al. 2003

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

We investigated the relation of expression of tumor-suppressor gene product p53, apoptosis-regulator gene product bcl-2, and CD34 (as a measure of microvessel density [MVD]) with traditional clinicopathologic prognostic variables in endometrial carcinoma (histologic type, grade, depth of myometrial invasion, angiolymphatic invasion, lymph node involvement). In specimens from 63 patients with endometrial carcinoma, the mean MVD (64.38+/-28.71 microvessels per 200x field) was not related to any clinicopathologic variables. Nuclear p53 expression was detected in 15 (23.8%) patients and was higher in nonendometrioid carcinomas (p<0.05) and in tumors with increasing histologic grade (p<0.001). Cytoplasmic bcl-2 staining was seen in 79.3% of the tumors. There was a negative correlation between bcl-2 expression and histologic type and tumor grade (p<0.05). In survival analysis, patient age, FIGO stage, high expression of p53, low expression of bcl-2, and high and intermediate MVD values were found to be the most significant prognostic indicators of survival (p<0.05). In multivariate regression analysis, FIGO stage and low bcl-2 expression were found to be the only independent indicators of prognosis (p<0.05).

show abstract

Section: Discussionsupporting

confidence: 89%

Angiogenesis, p53, and bcl-2 Expression as Prognostic Indicators in Endometrial Cancer

Erdem

Dursun

et al. 2003

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

show abstract

“…Many reports have stated that histological type and tumor grade are not correlated with the prognosis. [6][7]20 Our study showed that patients with hematogenous metastasis to organs other than lung (bone, brain, liver) had a signifi cantly poorer prognosis than those with metastasis only to lung. The median survival period of the patients with hematogenous metastasis to organs other than lung was 10.5 months and the longest survival was only 13 months.…”

Section: Discussionmentioning

confidence: 89%

Analysis of stage IVB endometrial carcinoma patients with distant metastasis: a review of prognoses in 55 patients

et al. 2009

View full text Add to dashboard Cite

show abstract

“…This subgroup represents 15% of all cases of EC, but accounts for 50% of EC-related deaths [31]. This patient population's survival is influenced by several factors including: histological subtype, and grade, extent of nodal involvement, and completeness of surgical resection [32,33,34,35,36].…”

Section: Treatment For Advanced Stage Endometrial Cancer (Stage Iii-iva)mentioning

confidence: 99%

Adjuvant therapy for endometrial cancer

2014

View full text Add to dashboard Cite

Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological factors. The objective of this manuscript is to review the evidence guiding adjuvant therapy for early stage and locally advanced uterine cancer. For patients with early stage disease, minimizing toxicity, while preserving outstanding cure rates remains the major goal. For patients with locally advanced endometrial cancer optimal combined regimens are being defined. Risk stratification based on molecular traits is under development and may aid refine the current risk prediction model and permit personalized approaches for women with endometrial cancer.

show abstract

Prognostic Indicators of Survival in Advanced Endometrial Cancer

Cited by 35 publications

References 0 publications

Angiogenesis, p53, and bcl-2 Expression as Prognostic Indicators in Endometrial Cancer

Angiogenesis, p53, and bcl-2 Expression as Prognostic Indicators in Endometrial Cancer

Analysis of stage IVB endometrial carcinoma patients with distant metastasis: a review of prognoses in 55 patients

Adjuvant therapy for endometrial cancer

Contact Info

Product

Resources

About